Abstract: The invention relates to novel dithiazole dioxides, to processes for their preparation and to their use in crop protection and in the protection of materials.

Abstract: Novel compounds of the formula I in which R is X is O or S, and R1, R2, R3, R4, R5 and R6 have the meaning indicated in patent claim 1, or a tautomeric ring-closed form, and the (E) isomers and their salts exhibit endothelin receptor-antagonistic properties.

Abstract: An injectable pharmaceutical composition for treatment of erectile dysfunction. The composition includes prostaglandin E-1, and optionally further includes levsin and/or additional vasodilators such as diltiazem HCl, verapamil, chlorpromazine, d,L-hyoscyamine, and 6,7-dimethoxy-1-veratrylisoquinoline HCl. The composition is effective for long-term restoration of normal erectile function to a patient having erectile dysfunction. The ability to reverse erectile dysfunction may be further enhanced by the inclusion of vitamin B-6, B-12, folic acid, and/or TPA. Also disclosed are methods for treatment and reversal of erectile dysfunction by injecting the pharmaceutical composition into the penis, either by subcutaneous or intracavernosal injection.

Abstract: Compounds of formula (I), wherein R1 represents a hydrogen atom or an optionally substituted alkyl, alkenyl, alkyloxiranyl, alkanoyl, alkoxycarbonyl, formyl, hydroxyalkyl, alkoxyalkyl, alkanoyloxyalkyl, hydroximinoalkyl, alkoxyiminoalkyl, hydrazonoalkyl or alkylhydrazonoalkyl group; R2 represents an alkoxy group; R3 and R4 each independently represent a hydrogen atom or an alkyl group; R5 represents an alkyl group, and R6 represents a group of formula —COOR7 or —CONR7R8, in which R7 and R8 show excellent fungicifal activity and systemicity and are thus useful in various agricultural applications.

Abstract: Compounds having the formula: are provided which are useful in the treatment of diseases associated with herpes viruses.

Abstract: Disclosed are novel 4,5-azolo-oxindoles having the formula These compounds inhibit cyclin-dependent kinases (CDKs), in particular CDK2. Thus, these compounds and their pharmaceutically acceptable salts, and *prodrugs of said compounds, are anti-proliferative agents useful in the treatment or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical compositions containing these compounds, and methods for the treatment and/or prevention of cancer, particularly in the treatment or control of solid tumors using these compounds, as well as intermediates useful in the preparation of compounds of formula I.

Abstract: This invention is directed to a broad spectrum antimicrobial composition which comprises a mixture of an iodopropynyl compound in combination with 2-(methoxycarbonylamino)benzimidazole and, where desirable, an algicide said mixture provided in an amount sufficient to protect a substrate from attack by one or more organisms. The composition can be used broadly in industrial systems and more particularly with substrates such as paints, coatings, stucco, concrete, stone, cementaceous surfaces, wood, caulking, sealants, textiles, leather, wood, preservatives, metal working fluids, drilling muds, clay slurries, glazes, optical brightness, carpet backing, pigments and as a preservative for other aqueous and wet state products, and the like.

Abstract: Hydantoin derivatives for eliminating free radicals and active oxygen which can be easily made into pharmaceutical preparations, show little, if any side effects, and are capable of being administered by the oral route. The pharmaceutical compositions for eliminating the active oxygen and the free radicals contain at least one hydantoin derivative represented by the following formula (I): wherein each of R1 and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives which have an action of eliminating the active oxygen and the free radicals are, accordingly, useful as pharmaceutical agents for treating a variety of diseases in which active oxygen and free radicals are involved or play a detrimental role.

Abstract: A method for a treatment of hyperplasia caused by papilloma virus, such as Condyloma acuminata, which comprises concomitantly topically and orally administering at least one tea catechin. Tea catechins do not involve the risk of side-effects and may be easily administered by the patients themselves.

Abstract: It is shown that the potency of anti-cancer drugs, here exemplified by doxorubicin, can be increased by the use of polyunsaturated fatty acid amides and in particular specific combinations of such compounds, forming complexes with doxorubicin. Further, a modified form of doxorubicin is presented.

Abstract: A compound of the formula wherein R1, R2, R3, R4 and Q are as defined above, are useful in the treatment of arthritis (including osteoarthritis and rheumatoid arthritis), cancer and other diseases. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID's), COX-2 inhibitors and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.

Abstract: A compound selected from the group consisting of a 5,6-dihydro-&agr;-pyrone of formula (I): wherein bond a is oriented either or ; X is O or NH; R1 is selected from the group consisting of: a group R3(O)C— wherein R3 is selected from the group consisting of: (i) a group of formula R4—CH═CH— wherein R4 is C1-C20 alkyl, C2-C20 alkenyl, an aryl group, or a 5- or 6-membered unsaturated heterocyclic ring containing one or two O, N or S atoms, (ii) C2-C20 alkyl; and (iii) an aryl group or a substituent which is a fused ring system of formula (1) or (2):  wherein each of R′ and R″, which are the same or different and may occupy any position on ring a or ring b of said fused ring system, is H or C1-C6 alkyl; a group ArCH2— wherein Ar is an aryl group; and a group R5O—CH2— wherein R5 is C1-C6 alkyl optionally interrupted by one or two O atoms; and R2 is CH3 or, when R1 is a group of formula (A) as defined below, R2 i

Abstract: Substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.

Abstract: Liquid vitamin C concentrate compositions comprise a mineral ascorbate and a pharmacologically acceptable liquid organic polyol solvent for the mineral ascorbate, the concentrate having a pH between about 5 and 7. The concentrate may also contain an aldonic compound and/or a pharmacologically acceptable zinc compound. The concentrate compositions are prepared by heating the solvent to 50-90° C. and mixing the ascorbate and/or aldonic compound and/or zinc compound into the heated solvent, preferably in the absence of oxygen. These concentrate compositions are also characterized as a composition which comprises the reaction product of a mineral ascorbate and a pharmacologically acceptable liquid organic polyol solvent and, optionally an aldonic compound and/or a soluble non-toxic zinc compound, which reaction product includes 4-hydroxy-5-methyl-3(2H)-furanone and/or 3-hydroxy kojic acid.

Abstract: A non-toxic environmentally friendly aqueous disinfectant is disclosed for specific use as prevention against contamination by potentially pathogenic bacteria and virus. The aqueous disinfectant is formulated by electrolytically generating silver ions in water in combination with a citric acid. The aqueous disinfectant may include a suitable alcohol and/or a detergent. The aqueous disinfectant has been shown to be very effective at eliminating standard indicator organisms such as staphylococcus aureus, samonella cholerasuis and Pseudomonas aeruginosa.

Abstract: Metal amino acid chelates for animals are beneficial for facilitating and promoting growth by increasing desired metallic ion uptake. The present invention is directed to a process for providing an animal fed additive by preparing metal amino acid chelates, and the metal amino acid chelate growth facilitator, promoter and enhancer prepared by the process.

Abstract: Methods of using the chromium(III) complex represented by the formula [Cr3O(O2CCH2CH3)6(H2O)3]+ as a nutritional supplement.

Abstract: Disclosed are compounds of the formula: R represents hydrogen or is a C-3 to C-6 cycloalkyl or C-4 to C-10 straight or branched carbon chain alkyl-cycloalkyl or a group —B—D, where B is C-2 to C-10 straight or branched carbon chain alkyl and D is hydroxy or alkyloxy or 2,3-dihydroxypropyl or 2,3-dialkyloxypropyl or 2,2-dialkyl-1,3-dioxolane-5-methyl, where alkyl is C-1 to C-10 straight or branched carbon chain; W represents CH(CH3)CH2—, C(CH3)2CH2—; Z represents hydrogen, —NHCOR2, —NHCONR2R3 or —NHSO2R2 or —NHSO2NR2R3 or —NHCOOR4 wherein R4 is alkyl of from 1 to about 6 carbon atoms, alkoxyalkyl wherein the alkyl groups may be the same or different and contain from 1 to about 6 carbon atoms, alkoxyaryl, cycloalkyl of from 3 to about 8 carbon atoms.

Abstract: The present invention relates new use of rhein or the salt thereof, that is new use in preparing medicine for treatment of diabetic nephropathy. A medicine containing rhein or the salt thereof for treatment of diabetic nephropathy may be supplied in aqueous solution or capsula for oral, the dosage is not larger than 200 mg/day. Toxicity of rhein or the salt thereof is low, LD50 is 3.2 g/kg. The concentration of medicine in blood is still higher in 24 hours after administered rhein by oral. Rhein can effectively control or decrease the hyperglycemia, suppress renal hypertrophy and kidney index in experimental diabetic rats. The urinary protein execretion was significantly decreased in the diabetic patients treated by rhein.

Abstract: A compound of the formula wherein R1 is a straight or branched alkyl group having from 1 to 6 carbon atoms, phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R2 is hydrogen or methyl; and R3 is hydrogen, methyl or carboxyl; which is useful in the treatment of seizure disorders. Processes are disclosed for the preparation of the compound. Intermediates prepared during the synthesis of the compound are also disclosed.

Abstract: The present invention describes impaired glutamate uptake in glioma cells, and further shows that instead of removing glutamate from the extracellular fluid, glioma cells release large amounts of glutamate. The high levels of extracellular glutamate result in elevated [Ca2+]i followed by widespread neuronal death, which could be prevented by treating neurons with the NMDA receptor antagonists, MK-801 or D-AP5, or by depletion of glutamate from the medium. Significantly, several phenylglycine derivatives, including the metabotropic glutamate receptor agonist/antagonist (S)-4-carboxyphenylglycine (S-4CPG), potently and selectively inhibited glutamate release from glioma cells and thereby prevented neurotoxicity.

Abstract: The present invention provides an antagonist for endothelin which is considered to have a relation to hypertension, Buerger is disease, asthma, eyegrounds diseases, and the like. Said endothelin antagonist contains 15-keto-prostaglandin E compounds, especially 13,14-dihydro-15-keto-16-mono or dihalo-prostaglandins.

Abstract: The compound is a neuropeptide Y antagonist and is effective in treating feeding disorders, cardiovascular diseases and other physiological disorders.

Abstract: A composition containing capsaicin together with other ingredients to neutralize the discomfort resulting from the application of capsaicin to the skin enabling treatment of many types of discomforts, including arthritis pain, neuropathy, post surgical scarring, hemorrhoid pain and itching, and pruritis without the discomfort normally associated with the topical application of capsaicin.

Abstract: Novel benzamidines, having LTB4-antagonistic activity, of the formula methods for their preparation, their and their use as medicaments.

Abstract: The present invention relates to chromotropic nitrone spin trapping agents, methods of making these agents, compositions comprising same, and methods of their use. In particular, azulenyl nitrones of the present invention are effective agents for trapping free radical species and find use as efficient antioxidants in physicochemical and biological systems. Accordingly, the invention also relates to spin adducts formed from the combination of azulenyl nitrones with free radicals. The compounds of the present invention are readily prepared from available starting materials and find further use in assays and in a number of diagnostic, prophylactic and therapeutic applications, including but not limited to the alleviation, modulation and inhibition of the negative effects of carbon-centered or oxygen-centered radical species and other products of oxidation. Moreover, the combination adducts may be calorimetrically detected and, optionally, isolated and characterized to obtain valuable information (e.g.

Abstract: Disclosed are novel &agr;-(2-hydroxyphenyl) nitrone compounds and pharmaceutical compositions containing such compounds. The disclosed compositions are useful as therapeutics for inflammation-related conditions in mammals, such as arthritis, and as analytical reagents for detecting free radicals.

Abstract: The present invention encompasses methods of treating patients for tobacco addiction and nicotine addiction, for palliating the effects of nicotine withdrawal, for providing or facilitating the effects of smoking cessation therapies and as long-term smoking cessation maintenance therapy. The invention also includes related pharmaceutical compositions comprising nicotine receptor antagonists and either an anti-depressant or an anti-anxiety drug. Specific combinations of drugs (mecamylamine HCl and bupropion HCl) as well as mecamylamine in combination with certain drug classes (e.g., anti-anxiety drugs and anti-depressants) comprise the pharmaceutical compositions disclosed. These compositions are also contemplated for use in the treatment of cocaine addiction and the treatment of alcohol dependence.

Abstract: Methods of preparing, and compositions comprising, derivatives of (+)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Abstract: An external preparation for topical administration which aims at inhibiting rejection reactions at organ or bone marrow transplantation or treating autoimmune diseases or allergic diseases and contains as the active ingredient 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol or a pharmaceutically acceptable acid addition salt thereof.

Abstract: A method is presented whereby sympathetically mediated pain relief is achieved through the periodic topical administration of compositions comprising tricyclic antipressants mixed with one or more topical bases, and applying to the skin above areas affected by pain. Dextromethorphan or ketamine from the pharmacological class of NMDA receptor antagonists is optionally combined. The topical vehicle bases which are needed to drive the pharmacological agents through the dermis into the subcutaneous tissue, either singly or in combinations, may be selected from the group comprising cocoa butter, aloe vera gel, aquafor, petroleum jelly, lecithin, and standard cold cream.

Abstract: This invention relates to a method of treating patients afflicted with septic shock. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.

Abstract: A composition and method for reducing serum cholesterol in humans and animals is provided. The method comprises administering phytosterol and policosanol which together produce a synergistic effect in lowering serum cholesterol levels. Preferably the administered composition includes about 3.2:1 parts by weight of phytosterol and policosanol.

Abstract: A method is provided for conferring neuroprotection on a population of cells in a subject, the method including providing a polycyclic compound having a terminal phenolic group in a structure containing at least a second ring, the compound having a molecular weight of less than 1000 Daltons, the compound not including estrogen compounds including estrogen agonists. The compound may be administered in an effective dose to the population of cells so as to confer neuroprotection. Methods are further provided for treating a neurodegenerative disease in a subject that include providing an effective dose of a formulation containing the compound and administering the dose to the subject.

Abstract: The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated stilbene, particularly resveratrol, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated stilbene to a herpes virus-infected site. The present invention also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of reducing the cytopathic effect of HSV on mammalian cells.

Abstract: Spherical particles having a size on the order of 0.1 to 100 microns in size are created by systems and devices of several types. The device includes a source of a stream of gas which is forced through a liquid held under pressure in a pressure chamber with an exit opening therein. The stream of gas surrounded by the liquid in the pressure chamber flows out of an exit orifice of the chamber into a liquid thereby creating a monodispersion of bubbles with substantially uniform diameter. The bubbles are small in size and produced with a relatively small amount of energy relative to comparable systems. Small particles of liquid may also be produced. Applications of the technology range from oxygenating sewage with monodispersions of bubbles to inhalation therapy with monodisperse aerosol dispersions of pharmaceutically active drugs.

Abstract: The invention relates to a process and an apparatus for preparing active ingredient dispersions, wherein an active ingredient is dissolved in a fluid gas, the fluid gas loaded with active ingredient is essentially completely dissolved in a liquid and is decompressed, and the gas is separated from the liquid loaded with active ingredient.

Abstract: A process for the preparation of an aqueous tar suspoemulsion includes the steps of mixing a mixture including (a) a viscous tar composition formed from a tar, from inorganic solids and, optionally, from water; (b) water (W); (c) a surface-active agent (SA) exhibiting a hydrophilicity/lipophilicity balance (HLB) of at least 10; and, optionally, (d) a thickening water-soluble polymer (TWP) with a molecular mass of greater than 10,000. The relative amounts of constituents (W), (SA) and, optionally, (TWP) are such that the viscosity of the (W)+(SA)+optional (TWP) mixture is preferably equal to or greater than the viscosity of the tar. An optional embodiment of the process provides for dilution of the mixture obtained with water or with an aqueous acidic solution.

Abstract: The present invention is directed to a process for separating polyester, and particularly polyethylene terephthalate, from various contaminants and impurities. In general, the process includes the steps of contacting materials containing polyester with an alkaline composition to form a mixture. The mixture is heated causing some of the impurities to be chemically modified into a more separable form. During heating, a portion of the polyester may also be saponified. After heating, the mixture can be washed with water and the polyester can be easily separated from the remaining impurities. Through the process of the present invention, polyester can be separated and recovered from waste materials containing polyvinyl chloride and aluminum. The process is also effective at removing coatings adhered to the polyester and at removing entrained organic and inorganic compounds contained within the polyester.

Abstract: Compact and preferably cellular polyurethane elastomers are prepared by reacting a) relatively high molecular weight polyhydroxyl compounds and if desired, b) low molecular weight chain extenders and/or crosslinkers with c) phenylene 1,4-diisocyanate (p-PDI) and at least one additional aromatic diisocyanate selected from the group consisting of tolylene diisocyanate, diphenylmethane diisocyanate, 3,3′-dimethylbiphenyl diisocyanate, 1,2-diphenylethane diisocyanate and/or aliphatic diisocyanate, having from 4 to 12 carbon atoms and/or cycloaliphatic diisocyanate having from 6 to 18 carbon atoms, where the formative components (a), (c) and, if used, (b) are advantageously reacted by the prepolymer method, in the presence or absence of d) catalysts, e) blowing agents and f) additives. Isocyanate prepolymers suitable for this purpose are described.

Abstract: A flexible, low density thermoplastic foam and a method for lowering the density and increasing the flexibility of a thermoplastic foam having a melting temperature and being either amorphous with a softening temperature or semicrystalline with a glass transition temperature.

Abstract: A crosslinked ethylene-olefin copolymer foam and a method for the production thereof are disclosed. The foam having a gel content of 70 to 99%, an apparent density of 0.2 to 0.02 g/cm3, 25% compression set at 40° C. of 0.1 to 20.0%, 25% compression hardness of 0.1 to 1.0 kgf/cm2, and Asker C type surface hardness of 3 to 40 is foamed from a copolymer of ethylene and &agr;-olefin having 3 to 18 carbon atoms, the copolymer having a melt flow rate (MFR) of 0.1 to 100 g/10 minutes, a critical shear rate (CSR) satisfying the equation: log[CSR]≦2.48+0.500×log[MFR], a density of 0.860 to 0.935 g/cm3, a Q value determined by the size exclusion chromatography (SEC) of 1.5 to 4, and an extrapolated end temperature of melting (Tem) of 65° C. to 130° C.

Abstract: This invention pertains to a process for the manufacture of a hydrophilic polymeric product, consisting in causing a material comprising a crosslinked silicone polymer matrix and photoinitiator groups dispersed and immobilized within the polymer matrix to swell in a swelling solution comprising a solvent for swelling the crosslinked silicone polymer of the matrix of the material, a photopolymerizable hydrophilic monomer and optionally a crosslinking agent and a proton- or electron-donating coinitiator compound, when the material comprises photoactivable photoinitiator groups and does not comprise proton- or electron-donating coinitiator groups causing the photopolymerizable hydrophilic monomer to diffuse into the swollen material, and polymerizing, by irradiation, the photopolymerizable hydrophilic monomer.

Abstract: A process for preparation of ceramic objects which comprises: (a) applying a layer of a high-solids photocurable ceramic composition, to a substrate, the composition comprising: (1) at least 10 percent by volume of water; (2) at least 0.05 percent by weight of photocurable compounds which are soluble or dispersible in water; and (3) at least 45 volume percent dispersed ceramic particles; and (b) subjecting the composition to sufficient ultraviolet radiation to react the compounds or polymers sufficiently to form a layer of the photocurable compounds or polymers, which is water-insoluble and non-dispersible in water, having the ceramic particles dispersed therein.

Abstract: A monomer useful in the formulation of a radiation curable coatable composition comprises (a) polyfunctional isocyanurate having at least three terminal reactive groups reacted with (b) hydroxyalkyl acrylate and (c) tertiary amine alcohol in a molar ratio of a:b:c of about 1:1-2.5:0.5-2, wherein b+c is at least 3 and no greater than the total number of terminal reactive groups of (a). The monomer is included in a radiation curable coatable composition suitable for use as a floor finish and in a floor finishing system comprising the foregoing coatable composition with a primer. A method for the treatment of a substrate using the floor finish and the floor finishing system is also described.

Abstract: The present invention relates to a hot melt adhesive composition useful for articles such as plasters, bandages and tapes which are adhesively adhered to skin. The adhesive may be coated continuously and preferably, discontinuously onto a substrate. More preferably, the hot melt adhesive composition is pattern-coated. The adhesive is permanently adhered to at least one substrate of the article and removably or releasably attachable to skin. The adhesive advantageously does not cause skin irritation nor transfers adhesive to the skin upon removal.

Abstract: The present invention is an endodontic sealer paste and an endodontic core material for root canal filling, retrofilling, and perforation repair. The endodontic sealer paste contains a dry poly(carboxylic acid), zinc oxide, and an aliphatic acid. The endodontic core material contains a pliant polymer, a dry poly(carboxylic acid), and zinc oxide.

Abstract: An oil-based ink for a printing plate by an ink jet process comprising spraying an oil-based ink comprising at least resin particles dispersed in a non aqueous carrier liquid having an electric resistance of 109 &OHgr;cm or more and a dielectric constant of 3.

Abstract: A composition comprising an ethylene containing polymer, a crosslinking agent and a treated filler material. The treated filler material comprises a treating agent which is a polymer comprising acrylonitrile and at least one other monomer. A preferred treated filler material is a treated carbon black and a preferred ethylene containing polymer is an ethylene vinyl acetate (EVA) polymer. A semiconductive composition of the present invention may be advantageously utilized in electrical wire and cable application.

Abstract: Organophilic phyllosilicates which have been prepared by treating a naturally occurring or synthetic phyllosilicate, or a mixture of such silicates, with a salt of a quaternary or other cyclic amidine compound, or with a mixture of such salts; polymeric systems, in particular thermoplastic polymers and thermosetting polymer systems, preferably epoxy resins, polyurethanes and rubbers, which comprise novel organophilic phyllosilicates, and also shapable moulding materials and finished mouldings in the form of composite materials, in particular in the form of nanocomposites.